BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36568559)

  • 1. CVD risk in non-albuminuric chronic kidney disease in hypertensive, non-diabetic subjects: A
    Sheng CS; Wang D; Yuan J; Cheng Y; Sun S; Yang Y; Miao Y; Wang W; Tian J; Bloomgarden ZT
    Front Cardiovasc Med; 2022; 9():977938. PubMed ID: 36568559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Kidney Disease Stage and Cardiovascular and Mortality Events Among Older Adults: The SPRINT Trial.
    Turbay-Caballero V; Ricardo AC; Chen J; Missikpode C; Lash JP; Aroca-Martinez G; Musso CG
    Kidney Med; 2024 Jul; 6(7):100845. PubMed ID: 38966681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy.
    Vaduganathan M; Pareek M; Kristensen AMD; Biering-Sørensen T; Byrne C; Almarzooq Z; Olesen TB; Olsen MH; Bhatt DL
    Eur J Heart Fail; 2021 Mar; 23(3):384-392. PubMed ID: 33448580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated Kidney Tubular Secretion and Kidney, Cardiovascular, and Mortality Outcomes in CKD: The Systolic Blood Pressure Intervention Trial.
    Ascher SB; Shlipak MG; Katz R; Bullen AL; Scherzer R; Hallan SI; Cheung AK; Raphael KL; Estrella MM; Jotwani VK; Seegmiller JC; Ix JH; Garimella PS
    Kidney Med; 2022 Dec; 4(12):100546. PubMed ID: 36507053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Urinary Dickkopf-3 Levels with Cardiovascular Events and Kidney Disease Progression in Systolic Blood Pressure Intervention Trial.
    Peschard VG; Scherzer R; Katz R; Chen TK; Bullen AL; Campos K; Estrella MM; Ix JH; Shlipak MG
    Kidney360; 2024 May; 5(5):690-697. PubMed ID: 38472135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study.
    Penno G; Solini A; Orsi E; Bonora E; Fondelli C; Trevisan R; Vedovato M; Cavalot F; Lamacchia O; Scardapane M; Nicolucci A; Pugliese G;
    Diabetologia; 2018 Nov; 61(11):2277-2289. PubMed ID: 30032426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated GFR Variability and Risk of Cardiovascular Events and Mortality in SPRINT (Systolic Blood Pressure Intervention Trial).
    Malhotra R; Katz R; Jotwani V; Agarwal A; Cohen DL; Cushman WC; Ishani A; Killeen AA; Kitzman DW; Oparil S; Papademetriou V; Parikh CR; Raphael KL; Rocco MV; Tamariz LJ; Whelton PK; Wright JT; Shlipak MG; Ix JH
    Am J Kidney Dis; 2021 Jul; 78(1):48-56. PubMed ID: 33333147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney Function as Risk Factor and Predictor of Cardiovascular Outcomes and Mortality Among Older Adults.
    Kühn A; van der Giet M; Kuhlmann MK; Martus P; Mielke N; Ebert N; Schaeffner ES
    Am J Kidney Dis; 2021 Mar; 77(3):386-396.e1. PubMed ID: 33197533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Rapid Kidney Function Decline, All-Cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes.
    Buyadaa O; Magliano DJ; Salim A; Koye DN; Shaw JE
    Diabetes Care; 2020 Jan; 43(1):122-129. PubMed ID: 31796570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
    Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney outcomes and all-cause mortality in people with type 2 diabetes exhibiting non-albuminuric kidney insufficiency.
    Yamamoto Y; Hanai K; Mori T; Yokoyama Y; Yoshida N; Murata H; Shinozaki T; Babazono T
    Diabetologia; 2022 Jan; 65(1):234-245. PubMed ID: 34739552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study.
    Penno G; Solini A; Bonora E; Orsi E; Fondelli C; Zerbini G; Trevisan R; Vedovato M; Cavalot F; Laviola L; Nicolucci A; Pugliese G;
    Acta Diabetol; 2018 Jun; 55(6):603-612. PubMed ID: 29574497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors and urinary biomarkers of non-albuminuric and albuminuric chronic kidney disease in patients with type 2 diabetes.
    Korbut AI; Klimontov VV; Vinogradov IV; Romanov VV
    World J Diabetes; 2019 Nov; 10(11):517-533. PubMed ID: 31798788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-normal albuminuria is strongly associated with incident chronic kidney disease in a nondiabetic population with normal range of albuminuria and normal kidney function.
    Okubo A; Nakashima A; Doi S; Doi T; Ueno T; Maeda K; Tamura R; Yamane K; Masaki T
    Clin Exp Nephrol; 2020 May; 24(5):435-443. PubMed ID: 32076888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic kidney disease, cardiovascular disease and mortality: A prospective cohort study in a multi-ethnic Asian population.
    Lim CC; Teo BW; Ong PG; Cheung CY; Lim SC; Chow KY; Meng CC; Lee J; Tai ES; Wong TY; Sabanayagam C
    Eur J Prev Cardiol; 2015 Aug; 22(8):1018-26. PubMed ID: 24857889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A
    Cherney DZI; Dagogo-Jack S; Cosentino F; Pratley RE; Frederich R; Maldonado M; Liu CC; Cannon CP
    Kidney Int Rep; 2022 Aug; 7(8):1782-1792. PubMed ID: 35967112
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.